|
Summary Information: Neoleukin Therapeutics Inc. Common Stock NASDAQ:NLTX |
  [email protected] |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Neoleukin's lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface.
__The following are links to various summary and news pages for __Neoleukin Therapeutics Inc. Common Stock [ NLTX ]. __Note: Some Links might not have information for the company. |
|